LONG
David Tyrrell has initiated and directed major research programs to encompass both creative basic research and clinical applications, and has authored co-authored over 100 publications. He was at the forefront of discovery of the antiviral activity for hepatitis B virus of purine dideoxynucleosides, and extension of this work to the discovery of a potent "blockbuster" new drug, lamivudine. This is the first oral antiviral agent for hepatitis B treatment and is currently licensed in over 120 countries. He is presently pursuing new approaches to circumvent clinical resistance to lamivudine. His seminal observations have altered significantly the management of hepatitis B, and his findings have also significantly enhanced the outcome of hepatitis B patients undergoing liver transplantation. He has received international recognition for this work, as demonstrated by invitations to present major addresses at state of the art meetings dealing with research and treatment of hepatitis B virus, as well as the awarding of major prizes including the Prix Galien Award (1998), the Alberta Order of Excellence (2000), and the appointment as an Officer of the Order of Canada (2002). In addition, he has demonstrated exceptional ability in the administration of a department, a major medical school and government committees.

SHORT
David Tyrrell was at the forefront of discovery of the antihepatitis B activity of purine dideoxynucleosides and extended the discovery to find a potent "blockbuster" new drug, Lamivudine. His seminal observations have altered significantly the management of hepatitis B.